Evidence map›Paper›PMID 42575864›Full record

ArticleHuman reproduction (Oxford, England)2026

The impact of menstrual cycle phase and BMI on mitochondrial dysfunction in PMOS endometrium.

L Luyckx, M Myllykangas, J Kinnunen, S Lukashevich, A Salumets, A Velthut-Meikas, I Rooda, V Izzi, R K Arffman, U Saarela and 1 more

Abstract read
In one paragraph

Article in Human reproduction (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

L LuyckxDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0000-0001-5545-098X
M MyllykangasDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0009-0008-8472-2954
J KinnunenDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0000-0001-5287-7582
S LukashevichImplantation, Placentation, Pregnancy and Endometriosis (POPPYe) Research Group, Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium.
A SalumetsDepartment of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Tartu and Celvia CC, Tartu, Estonia.ORCID 0000-0002-1251-8160
A Velthut-MeikasDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0003-1927-9016
I RoodaDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.ORCID 0000-0002-5594-4987
V IzziFaculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.ORCID 0000-0002-9960-4917
R K ArffmanDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0000-0003-3277-9293
U SaarelaDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0000-0002-9410-6548
T T PiltonenDepartment of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University of Oulu, Oulu University Hospital, Oulu, Finland.ORCID 0000-0002-9921-7300

Funding

Estonian Research Council PRG1076Estonian Research Council PSG608Horizon 2020 Marie-Curie MATER Innovative Training Network H2020-MSCA-ITN-2018Horizon Europe grant NESTOR 101120075Jusélius FoundationNovo Nordisk Foundation NNF21OC0070372Novo Nordisk Foundation NNF24OC0092384Novo Nordisk Foundation and Research Council of Finland 321763Research Council of Finland 315921Research Council of Finland 336449Swedish Research Council 2024-02530University of Oulu Profi6 Fibrobesity Programme 336449University of Oulu Scholarship Foundation
6 · The paper itself

Abstract

study questionDoes the endometrium of oligo-ovulatory women with polyendocrine metabolic ovarian syndrome (PMOS) exhibit menstrual cycle phase-specific transcriptomic alterations compared to women without PMOS? SUMMARY ANSWER: Compared to healthy controls, women with PMOS exhibit endometrial transcriptomic dysregulations which are menstrual cycle phase-specific and, most notably, related to mitochondrial function. WHAT IS KNOWN ALREADY: Infertility and gestational dysfunction in women with PMOS are increasingly attributed to endometrial abnormalities, yet the underlying mechanisms behind PMOS-related endometrial dysfunction remain unclear. Previous studies have focused on anovulatory phenotypes, resulting in a poor understanding of cycle phase-specific defects in the endometria of women with PMOS. STUDY DESIGN, SIZE, DURATION: Endometrial biopsies were obtained from oligo-ovulatory women with PMOS and healthy controls at four distinct menstrual cycle phases (proliferative, early-, mid-, and late-secretory phases) and subjected to RNA sequencing. Parallel in vitro experiments were conducted using cultured endometrial stromal cells (ESCs) and epithelial organoids (EEOs) derived from an additional endometrial sample cohort. PARTICIPANTS/MATERIALS, SETTING,

methodsRNA sequencing was performed on biopsies from 78 (oligo-)ovulatory women, age- and BMI-matched between PMOS (n = 39) and control (n = 39) groups. Phase-specific transcriptomic profiles and pathway enrichment analyses were performed. For functional assays, endometrial cells were isolated from four PMOS and four control donors per BMI group (lean: < 25 kg/m2; obese: ≥30 kg/m2). Mitochondrial function, including respiration, ATP and reactive oxygen species production, and membrane potential, was assessed in both cell types before and after hormonal exposure. MAIN RESULTS AND THE ROLE OF CHANCE: Endometrial transcriptomes clustered primarily by cycle phase; however, PMOS-specific dysregulation was observed related to extracellular matrix organization, estrogen receptor (ESR) signaling, ion transport, and mitochondrial respiratory function. Gene trajectory analyses revealed phase-specific alterations in progesterone-, insulin signaling-, and mitochondria-related gene expression during the early-secretory phase, and epithelial function during the mid-secretory phase. Functionally, decidualized ESCs from obese PMOS women displayed reduced mitochondrial respiration, whereas EEOs from lean PMOS patients exhibited increased mitochondrial activity. LARGE SCALE DATA: Sequencing data are available from the corresponding author upon request. LIMITATIONS, REASONS FOR CAUTION: Women with PMOS were oligo-ovulatory while controls exhibited regular cycles. The sample size for in vitro studies was modest, warranting validation in larger cohorts. Additionally, the use of bulk RNA sequencing may obscure cell-type-specific transcriptomic signatures, emphasizing the need for future single-cell approaches to dissect cellular heterogeneity in PMOS endometrium. WIDER IMPLICATIONS OF THE

findingsThis study uncovers dynamic, cycle phase-dependent molecular and bioenergetic alterations in the endometrium of oligo-ovulatory women with PMOS. Mitochondrial dysfunction, particularly during the implantation window, emerges as a key pathological feature. The observed BMI-dependent divergence in mitochondrial function suggests that personalized therapeutic strategies may be necessary to improve reproductive outcomes in women with PMOS.

fundingFunded by the Jusélius Foundation, Novo Nordisk Foundation, Research Council of Finland, and the Horizon 2020 Marie-Curie MATER Innovative Training Network (all to T.T.P.), with additional support from the University of Oulu Scholarship Foundation (L.L.), the Estonian Research Council (E.V.M. and I.R.), and the Estonian Research Council grant no. PRG1076, Swedish Research Council grant no. 2024-02530, Novo Nordisk Foundation grant no. NNF24OC0092384 and Horizon Europe grant NESTOR, grant no. 101120075 (A.S.). DISCLOSURES: The authors declare no competing interests.

Indexed as

Body Mass IndexEndometriumMenstrual CycleMitochondriaOvarian DiseasesAdultCase-Control StudiesFemaleHumansTranscriptomeendometriummitochondriaorganoidsPCOSPMOStranscriptome

Identifiers

PMID42575864
PMCPMC13635459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.